Product Description
Mechanisms of Action: NOGO Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis
Phase 1: Amyotrophic Lateral Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | N/A |
Not yet recruiting |
Breast Cancer |
2019-12-31 |
|
Ozanezumab Phase II study in patients with ALS | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2015-06-06 |
|
NCT01753076 | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2015-01-22 |
|
NCT01435993 | P1 |
Terminated |
Multiple Sclerosis, Relapsing-Remitting |
2012-01-23 |
22% |